No Axillary sUrgical Treatment In Clinically Lymph Node Negative Patients After UltraSonography
NCT ID: NCT04303715
Last Updated: 2023-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
1734 participants
INTERVENTIONAL
2020-09-15
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
NAUTILUS study aim to establish the minimally invasive treatment of breast cancer by reexamining the necessity of sentinel lymph node biopsy among patients with invasive breast cancer who have tumors under 5cm, are clinically node-negative, and are having breast conserving surgery performed.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Axillary ultrasound can effectively exclude high nodal burden, showing 95% NPV in a systematic review.
SLNB has morbidity including lymphedema, limited range of motion, pain, and other post-surgical complications, eventually leading to reduced quality of life.
Considering improvement of imaging modalities and adjuvant care, survival outcome of SLNB must be re-evaluated. Especially research reflective of the regional specificities of Korea and Asia-Pacific is needed.
\[Study design\] Prospective, Multicenter, RCT.
\[Statistical considerations\] According to Z0011 trial, 5yr DFS in eligible patients is expected to be 86%, which is between previous data of 88.6% in cT1,2 and SN-negative patients4, and 83.9% in cT1,2 and 1-2 SN-positive patients.
Non-inferiority margin is set at 5%. With 5% significance level and 80% power, 780 patients are needed in each group. Assuming a 10% drop out rate, 1734 patients need to be recruited.
\[Screening and Randomization\] Participants undergo screening tests that assess eligibility according to inclusion/exclusion criteria.
In order to identify axillary lymph node metastases, axillary ultrasound is first performed by radiologists. Patients showing normal features are enrolled, while for conditionally normal patients, with only 1 suspicion of low nodal burden, axillary lymph node biopsy should be performed. Suspicious patients are excluded under following conditions: patients with 1 or more suspicion of high nodal burden, 2 or more suspicion of low nodal burden, or T2 invasive lobular carcinoma patients with 1 or more low nodal burden. The severity of nodal burden is defined through the criteria.
Patients who underwent radiological axillary staging are randomly assigned (1:1) to the study arm and the control arm before surgical care. Stratification is done based on trial centers and tumor sizes.
\[Post-surgical care\] All patients are planned to receive ipsilateral whole breast radiation. Patients randomized to non-SLNB arm are recommended to follow high tangential radiotherapy protocol, in which upper margin of radiation field includes axillary level I and II or lies within 2CM from humeral head.
Additional treatment may be performed if deemed necessary by the researcher
\[Objectives\]
1. Primary objective
\- 5yr invasive Disease Free Survival
2. Secondary objectives
* 5yr Overall Survival
* 5yr Distant Metastasis Free Survival
* Axillary recurrence rate
* Patient reported AE
* QoL
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No SLNB group
The study arm - BCS without SLNB
No SLNB
BCS only. Ommission of SLNB by axilla ultrasonography among selective breast cancer patients
SLNB group
The Control Arm - BCS with SLNB(+/-ALND)
SLNB
BCS with SLNB(+/-ALND)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No SLNB
BCS only. Ommission of SLNB by axilla ultrasonography among selective breast cancer patients
SLNB
BCS with SLNB(+/-ALND)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Invasive unilateral breast carcinoma with histological confirmation
* History of invasive breast cancer
* Histologically or radiologically no suspicion of distant metastases
* Performance status corresponding to ECOG grade 0-2
* Tumor size clinically and radiologically ≤ 5cm, independent of hormone receptor and HER2 status
* Clinically and sonographically negative axillary lymph nodes before biopsy; core needle biopsy or fine needle aspiration of suspicious lymph node required
* BCS candidate with postoperative whole-breast irradiation and adequate systemic therapy
* No psychological and geographical restriction in follow-up
* Written informed consent
Exclusion Criteria
* Bilateral breast cancer
* Invasive breast cancer treated with neoadjuvant therapy
* Tumor size clinically and radiologically \> 5cm
* Mastectomy candidate
* Pregnancy and breastfeeding
* Male breast cancer
* Unable to understand and fill out questionnaires
19 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Evidence-Based Healthcare Collaborating Agency
OTHER_GOV
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wonshik Han
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jung JG, Ahn SH, Lee S, Kim EK, Ryu JM, Park S, Lim W, Jung YS, Chung IY, Jeong J, Chang JH, Shin KH, Chang JM, Moon WK, Han W. No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: protocol of a prospective randomized clinical trial. BMC Cancer. 2022 Feb 20;22(1):189. doi: 10.1186/s12885-022-09273-1.
Chang JM, Shin HJ, Choi JS, Shin SU, Choi BH, Kim MJ, Yoon JH, Chung J, Kim TH, Han BK, Kim HH, Moon WK. Imaging Protocol and Criteria for Evaluation of Axillary Lymph Nodes in the NAUTILUS Trial. J Breast Cancer. 2021 Dec;24(6):554-560. doi: 10.4048/jbc.2021.24.e47. Epub 2021 Nov 24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NAUTILUS study
Identifier Type: -
Identifier Source: org_study_id